Noscapine inhibits human prostate cancer progression and metastasis in a mouse model.

Abstract

Oral administration of noscapine limited tumour growth and lymphatic metastasis of PC3 human prostate cancer in this mouse model, supporting its therapeutic potential as a nontoxic and easily administered treatment for metastatic cancer.